hypofractionated proton therapy for benign intracranial brain tumors, the hippi study

Conditions: Grade I Meningioma; Grade II Meningioma; Grade III Meningioma; Intracranial Neoplasm; Nerve Sheath Neoplasm; Pituitary Gland Adenoma; Schwannoma

Summary: this phase ii trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. a shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.

primary objective: i. to report 3 year local tumor control of moderately hypofractionated proton or photon therapy for benign intracranial tumors. secondary objectives: i. to demonstrate feasibility of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors. ii. to report physician reported acute and late toxicity of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors according to common terminology criteria for adverse events (ctcae) version 5.0. iii. to report neurocognitive effects, health related quality of life, and patient reported toxicity for moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors. outline: patients are assigned to 1 of 2 cohorts. cohort i: patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, monday-friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity. cohort ii: patients with pathologically confirmed world health organization (who) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, monday-friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed up periodically.

Eligibility criteria:
inclusion criteria: * pathologically or radiographically diagnosed benign intracranial or nerve sheath tumor, including meningiomas, pituitary adenomas, schwannomas. world health organization (who) grade 2-3 meningiomas are also allowed * recommended to receive proton or photon fractionated radiation therapy * signed informed consent exclusion criteria: * pregnant females are excluded. female of child-bearing potential (fcbp) must have a negative serum or urine pregnancy test prior to starting therapy. fcbp must agree to use adequate contraception (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study. should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. * a female of childbearing potential (fcbp) is a sexually mature woman who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (if age \>= 55 years); if the female subject is \ = 1 year her reproductive status has to be verified by additional laboratory (lab) tests (\ 40 in women not on estrogen replacement therapy) * prior radiation therapy that would overlap with current target volume * inability to undergo magnetic resonance imaging (mri)